Lu (Maggie) Qian: How Adaptive Trial Design Reveals Treatment Effects in COVID-19
Lu (Maggie) Qian, Founder at Zetyra, Creator and Editor at Evidence in the Wild, shared a post on LinkedIn:
”Four randomized controlled trials of IL-6 receptor antagonists in COVID-19 showed no significant benefit.
Then Remap-cap reported that tocilizumab and sarilumab both worked, with >99.9% posterior probability of superiority and confirmed survival benefit at six months.
The difference wasn’t the drug. It was the design.
Remap-cap used a multifactorial platform design.
Patients were randomized across multiple domains simultaneously, corticosteroids, IL-6 antagonists, anticoagulation, antivirals, convalescent plasma, and a Bayesian model learned which components worked, and for whom, across all domains at once.
Earlier trials enrolled less severely ill patients.
Remap-cap enrolled ICU patients.
It allowed concurrent dexamethasone.
And it had the statistical machinery to isolate the IL-6 effect on top of steroids.
It detected what single-question trials could not.
Then the same platform revealed a different vulnerability.
While the corticosteroid domain was randomizing hydrocortisone vs. no hydrocortisone, the recovery trial announced that dexamethasone reduced mortality.
Overnight, 93% of patients were receiving corticosteroids as background therapy regardless of randomization.
The adaptive engine worked as designed. It just didn’t work fast enough.
A simple, large trial answered the question before the more sophisticated Bayesian platform could.
No amount of pre-specification can fully anticipate the information environment a trial will encounter.
Meanwhile, most Phase III trials use covariate-adaptive randomization, and then analyze the data as though they used simple randomization, leaving power on the table.
Corrected inference methods exist.
The carat R package implements them.
Most practicing biostatisticians haven’t heard of it.
Randomization determines what a trial can learn, not just who gets what treatment.
It should be one of the first design decisions.
Not the last.”
Stay updated with Hemostasis Today.
-
Jun 4, 2026, 05:42Subramamyam Penubaku: Early Recognition and Risk-Based Management of Acute Pulmonary Embolism
-
Jun 4, 2026, 05:30Raghavendra Rao: Early Endothermal Ablation and Contemporary Management of Superficial Venous Thrombosis
-
Jun 4, 2026, 05:18Fouad Mikhail: Mechanical Thrombectomy and Anticoagulation in Intermediate-Risk Pulmonary Embolism
-
Jun 3, 2026, 17:18Giacomo Rossi: Cysteine and Gut Health – MIT Finds the Switch
-
Jun 3, 2026, 17:00Amin Ullah: Presence of RBCs of Unequal Sizes in a Peripheral Blood Smear – Anisocytosis of RBC
-
Jun 3, 2026, 16:59Jean Connors: Discussing Cancer-Associated Thrombosis at the Japanese Society of Thrombosis and Hemostasis
-
Jun 3, 2026, 16:54Ayush Bhowmik: Failed Drug Became the World’s Most Widely Used Blood Thinner
-
Jun 3, 2026, 16:13Salvador Payán Pernía: Arguing against a Significant Role for Erythropoietin Analogues in the Management of PRCA
-
Jun 3, 2026, 16:08Pedro Henrique Las Casas: How Anticoagulant Agents and Quercetin Influence Cancer Cell Procoagulant Activity